Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Anoro

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

Merck to expand respiratory disease portfolio with $10bn Verona acquisition

The deal includes a drug approved in the US for chronic obstructive pulmonary disease

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

- PMLiVE

GSK shares promising phase 3 results for linerixibat in PBC-related itch

Pruritus is experienced by up to 90% of patients with the rare liver disease

- PMLiVE

GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

- PMLiVE

GSK’s five-in-one meningococcal vaccine recommended by CDC advisory committee

Penmenvy combines the antigenic components of GSK's approved Bexsero and Menveo vaccines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links